By Josh White
Date: Wednesday 27 Aug 2025
(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset, bexmarilimab, through late-stage development in high-risk myelodysplastic syndromes (HR-MDS).
By Josh White
Date: Monday 18 Aug 2025
(Sharecast News) - Faron Pharmaceuticals said on Monday that it has secured a clear regulatory pathway for the potential approval of its lead cancer therapy bexmarilimab, following positive feedback from the US Food and Drug Administration.
By Josh White
Date: Wednesday 21 May 2025
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Ralph Hughes as its chief business officer on Wednesday, effective 28 May, as the clinical-stage biopharma firm sharpened its focus on commercial strategy, business development and market access.
Currency | UK Pounds |
Share Price | 205.00p |
Change Today | 5.00p |
% Change | 2.50 % |
52 Week High | 262.50p |
52 Week Low | 141.67p |
Volume | 42,442 |
Shares Issued | 116.95m |
Market Cap | £239.76m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 1 |
Buy | 3 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 1 |
Total | 6 |
No dividends found |
Time | Volume / Share Price |
15:08 | 1,000 @ 200.60p |
14:54 | 480 @ 209.00p |
14:03 | 1,001 @ 200.60p |
13:24 | 370 @ 209.00p |
10:54 | 32 @ 198.80p |
CFO | Yrjö E K Wichmann |
CEO | Juho Jalkanen |
Chair | Tuomo Pätsi |
You are here: research